Astellas Pharma Inc ALPMF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALPMF is a good fit for your portfolio.
News
-
Merck, Pfizer, Astellas Get FDA OK For Expanded Use Of Keytruda Plus Padcev
-
Astellas, Seagen: Cancer Treatment Padcev Supplemental Biologics License Application Gets FDA Priority Review
-
Merck, Seagen, Astellas Phase 3 Bladder Cancer Study Hits Endpoints
-
Apellis Pharmaceuticals shares rally as competing eye treatment fails to impress analysts
-
Poseida Therapeutics Shares Leap on Astellas Investments
-
Poseida Therapeutics in $50 Million Investment Deal With Astellas
-
Foreign businesses in China fear they're being targeted in a 'campaign' of government crackdowns. It's probably not that simple.
-
Stocks close lower, Nasdaq misses bear-market exit as risks at regional banks, rate hikes take focus
Trading Information
- Previous Close Price
- $9.84
- Day Range
- $9.52–9.52
- 52-Week Range
- $9.13–17.00
- Bid/Ask
- $9.13 / $10.18
- Market Cap
- $17.07 Bil
- Volume/Avg
- 200 / 4,114
Key Statistics
- Price/Earnings (Normalized)
- 15.12
- Price/Sales
- 1.57
- Dividend Yield (Trailing)
- 4.81%
- Dividend Yield (Forward)
- 5.01%
- Total Yield
- 7.34%
Company Profile
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 14,484
- Website
- http://www.astellas.com
Comparables
Valuation
Metric
|
ALPMF
|
4568
|
4519
|
---|---|---|---|
Price/Earnings (Normalized) | 15.12 | 41.92 | 27.16 |
Price/Book Value | 1.60 | 5.72 | 5.21 |
Price/Sales | 1.57 | 6.03 | 8.18 |
Price/Cash Flow | 8.66 | 32.72 | 25.50 |
Price/Earnings
ALPMF
4568
4519
Financial Strength
Metric
|
ALPMF
|
4568
|
4519
|
---|---|---|---|
Quick Ratio | 0.69 | 2.74 | 4.21 |
Current Ratio | 0.91 | 3.49 | 5.53 |
Interest Coverage | 2.62 | 11.76 | — |
Quick Ratio
ALPMF
4568
4519
Profitability
Metric
|
ALPMF
|
4568
|
4519
|
---|---|---|---|
Return on Assets (Normalized) | 1.82% | 7.33% | 17.64% |
Return on Equity (Normalized) | 3.43% | 13.01% | 21.05% |
Return on Invested Capital (Normalized) | 2.54% | 11.32% | 20.98% |
Return on Assets
ALPMF
4568
4519
Drug Manufacturers - General Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Trzljktpt | Cfh | $700.9 Bil | |
JNJ
| Johnson & Johnson | Wrxbmtqb | Dxzs | $353.8 Bil | |
MRK
| Merck & Co Inc | Slgphtl | Fvgl | $329.6 Bil | |
ABBV
| AbbVie Inc | Hmlzskcqm | Ztk | $286.0 Bil | |
AZN
| AstraZeneca PLC ADR | Mntdwgywms | Zbmd | $232.4 Bil | |
NVS
| Novartis AG ADR | Ytvpfrqm | Kjs | $198.4 Bil | |
RHHBY
| Roche Holding AG ADR | Typxqjxv | Htvxd | $195.3 Bil | |
AMGN
| Amgen Inc | Hjcjpqndm | Vws | $148.2 Bil | |
PFE
| Pfizer Inc | Tdvwpkqz | Ppl | $145.2 Bil | |
SNY
| Sanofi SA ADR | Qsgykrh | Mwmpv | $122.2 Bil |